(CATX) Perspective Therapeutics - Ratings and Ratios

Perspective Therapeutics, Inc. (NYSE MKT: CATX), formerly known as Isoray, Inc., is a biotechnology company specializing in the development of precision-targeted alpha therapies (TAT) for oncology. The company focuses on treating various types of cancer, including metastatic diseases, through innovative therapeutic approaches. Its lead product candidates include VMT-a-NET and VMT01, both currently in Phase 1/2a clinical trials.

VMT-a-NET is being evaluated for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors who have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera. VMT01 is being tested for the second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. The company has a clinical trial collaboration with Bristol Myers Squibb to assess the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in melanoma patients with positive MC1R imaging scans.

Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington. The company changed its name from Isoray, Inc. to Perspective Therapeutics, Inc. in February 2022. For more information, please visit their website at https://www.perspectivetherapeutics.com.

Ticker Symbol: CATX; Exchange: NYSE MKT; Type: common stock; Country Origin: United States; GICS Sub Industry: Health Care Equipment

Resistance: 6.2; Resistance: 4.1; Resistance: 2.6

Average Volume 20d: 599,642; Last Price: 2.46; SMA 20: 2.99; SMA 50: 3.23; SMA 200: 9.61; ATR: 0.26

Market Cap: $186.54M USD; P/E: 0.00; P/E Forward: 0.00; P/B: 0.57; P/S: 119.81; RoE: -19.42

3-Month Forecast: Based on technical indicators, the stock may face resistance at 6.2, 4.1, and 2.6. The SMA 20 and SMA 50 are above the current price, indicating potential bearish momentum. The ATR of 0.26 suggests moderate volatility. Fundamentally, the companys market cap and negative P/E ratio indicate high risk. The P/S ratio of 119.81 signals rich valuation relative to sales. The negative RoE of -19.42 reflects poor profitability. Overall, the stock is expected to remain under pressure in the coming months, with potential downside targeting the lower resistance levels.